Evidence map›Paper›PMID 40419601›Full record

ArticleScientific reports2025

Enhanced colon-targeted drug delivery through development of 5-fluorouracil-loaded cross-linked mastic gum nanoparticles.

Umme Hani, Nawaz Mahammed, T Reshma, Sirajunisa Talath, Adil Farooq Wali, Abdullah Aljasser, Adel Al Fatease, Ali H Alamri, Sharuk Khan

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Umme HaniDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
Nawaz MahammedDepartment of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research, K.R. Palli Cross, Anantapur, Chiyyedu, 515721, Andhra Pradesh, India. mohammednawaz151@gmail.com.
T ReshmaDepartment of Pharmaceutical Quality Assurance, Raghavendra Institute of Pharmaceutical Education and Research, K.R. Palli Cross, Anantapur, Chiyyedu, 515721, Andhra Pradesh, India.
Sirajunisa TalathRAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah, United Arab Emirates.
Adil Farooq WaliRAK College of Pharmacy, RAK Medical & Health Sciences University, Ras Al Khaimah, United Arab Emirates.
Abdullah AljasserDepartment of Pharmaceutics, College of Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam, 31441, Saudi Arabia.
Adel Al FateaseDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
Ali H AlamriDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
Sharuk KhanDepartment of Pharmaceutical Chemistry, N.B.S Institute of Pharmacy, Ausa, latur, Maharashtra, India.

Funding

King Khalid University RGP.2/21/46
6 · The paper itself

Abstract

This study explored the development of a novel colon-specific drug delivery system for 5-fluorouracil (5-FU) using cross-linked mastic gum (MG) nanoparticles (NPs). The primary goal is to enhance the treatment efficacy of colon cancer while minimizing systemic side effects. We employed Fourier Transform Infrared Radiation (FTIR) and Scanning Electron Microscopy (SEM) for the detailed characterization of the samples. FTIR analysis confirmed the successful cross-linking of MG, whereas SEM images revealed the spherical and uniform morphology of the NPs. Additionally, analysis of drug encapsulation efficiency (83.53%), particle size (240 nm), and drug release kinetics (zero-order), and the drug release percentage (95.20% ) were analyzed. The results demonstrated that MG NPs effectively encapsulated and controlled the release of 5-FU in a colon-targeted manner. This study recommends the proposed drug delivery system because of its potential to improve the outcomes of colon cancer treatment.

Indexed as

ColonColonic NeoplasmsDrug Delivery SystemsFluorouracilMastic ResinNanoparticlesDrug CarriersDrug LiberationHumansParticle SizeSpectroscopy, Fourier Transform InfraredDrug CarriersFluorouracilMastic Resin5-FluorouracilColon cancerDrug deliveryMastic gumNanoparticlesPolymerSodium tri-metaphosphate

Identifiers

PMID40419601
PMCPMC12106636

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.